Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $5.67.

A number of analysts have commented on the stock. StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research report on Thursday. They set a “sell” rating on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday, May 15th.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System raised its holdings in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 31,003 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Sangamo Therapeutics by 103.9% in the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 92,002 shares during the last quarter. Golden State Equity Partners raised its holdings in shares of Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 34,960 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the 1st quarter worth about $331,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $0.32 on Friday. The stock has a market capitalization of $66.92 million, a P/E ratio of -0.17 and a beta of 1.24. The firm’s fifty day simple moving average is $0.52 and its two-hundred day simple moving average is $0.61. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.67.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The firm had revenue of $0.48 million for the quarter, compared to the consensus estimate of $8.51 million. Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. During the same period last year, the company posted $0.12 EPS. As a group, research analysts predict that Sangamo Therapeutics will post -0.55 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.